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Abstract
A selective and sensitive reverse phase high performance liquid chromatographic (RP-HPLC) method has been 
developed for the separation and quantification of metformin HCl (MET) and vildagliptin (VILD) in tablet 
dosage form. The determination was carried out using phenomenax C18 column (4.6×150 mm) as a stationary 
phase and mobile phase comprised of phosphate buffer (pH6.0): methanol (65:35v/v). The pH of phosphate 
buffer is adjusted to 6.0 by using orthophosphoric acid. The flow rate was maintained at 1.0ml/min and the 
eluent  was  monitored  at  255nm.The  retention  time  of  MET and  VILD  were  1.503  min  and  5.530  min 
respectively. The method was validated in terms of linearity, precision, accuracy, ruggedness, specificity and 
robustness. The method was linear over the range 50-150 µg/ml for both MET (r = 0.999) and VILD (0.998).  
For precision studies; RSD for MET and VILD were 0.24 and 0.14 respectively. The percentage recoveries for 
both drugs from their tablets were 100.16 and 99.98 respectively. Inter-day; intra-day RSD for both drugs were 
found be 0.27 and 0.26, 0.13 and 0.29 respectively. 
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1. Introduction
MET  is  chemically,1-carbamimidamido-N,  N 
dimethyl  methanimidamide  Hydrochloride  an  anti-
diabetic drug given by oral route in the treatment of 
type  II  diabetes.  It  is  official  in  Indian 
Pharmacopoeia,  British  Pharmacopoeia,  European 
Pharmacopoeia and United States Pharmacopeia BP. 
All  the  pharmacopoeias  describe  HPLC method for 
estimation of MET. VILD is chemically(S)-1-[N-(3-
hydroxy-1-adamantyl)  glycyl]  pyrrolidine  2-
carbonitrile used as oral hypoglycemic agent. It is not 
official  in  any  Pharmacopoeia.  A  literature  survey 
revealed  spectrophotometry1,  HPLC2,3,  LC-MS/MS4 
and  LC-electrospray  tandem  mass  spectrometry5-9, 
methods  for  simultaneous  estimation  of  MET  in 
pharmaceutical  formulation  and  Few  UV-
Spectrophotometric  methods10,11,HPLC12-15,  and  ion-
pair HPLC16,other17,18.  MET 500mg and VILD 50mg 
in combination are available in market by brand name 
Galvus  MetTM which  is  an  anti-diabetic  agent.  The 
structure of a) Metformin HCL and b) Vildagliptin is 
shown in figure 1.
A literature survey reveals that there are no 
analytical  methods  reported  for  the  simultaneous 
determination  of  these  drugs  in  combined  dosage 
form. The present study reports a simple, accurate and 
precise  RP-HPLC  method  for  simultaneous 
determination of  Metformin HCl  and  Vildagliptin in 
combined tablet dosage form.
2. Material and Methods
2.1 Instrumentation
The  separation  of  MET  and  VILD  was 
achieved by using HPLC pump Spectra System 600E 
with Phenomenax C18 {4.6 x 150 mm} column and 
PDA-996 detector connected to EMPOWER Software 
was used for the study.
2.2 Reagents and Chemicals
MET and VILD were kindly obtained from 
Piramal  Healthcare  limited  and  Novartis  limited 
respectively.  Galvus  MetTM tablets  500mg  were 
purchased  from  the  local  market. HPLC  grade 
methanol and phosphate buffer were used. Deionized 
was used throughout the experiment. 
2.3 Optimized Chromatographic Conditions
A phenomenax  C18 (4.6×150 mm), column 
was  used  for  the  separation  of  drugs.  The  mobile 
phase  comprised  of  methanol  and  phosphate  buffer 
and in proportion of 35:65(v/v) with pH of phosphate 
buffer  adjusted to  (6.0)  using orthophosphoric acid. 
Injection volume was 20μl and run time was 15min 
and flow rate1.0ml/min. The column was maintained 
at ambient temperature and the eluent was detected at 
288nm.  The  separation  of  MET  and  VILD  under 
optimized condition is shown in Figure 2.
2.4 Preparation of Standard solution:
Standard stock solution (1000μg/ml) of MET 
and VILD were prepared by mixing in mobile phase 
comprised of methanol: phosphate buffer 35:65 (v/v). 
The  working  standard  solutions  were  prepared  and 
further diluted with mobile phase to contain a mixture 
of MET and VILD over the linearity range from 10-
50 μg/ml and 50-125 μg/ml respectively.
2.5 Preparation of Sample solution:
Twenty  tablets  were  weighed  and  finely 
powdered .A quantity of powder equivalent to 500 mg 
of  MET  and  50  mg  of  VILD  was  weighed  and 
transferred to a 100 ml volumetric standard flask and 
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mixed with 50 ml of mobile phase. The sample was 
kept in an ultrasonic bath for 20 min and volume was 
made to 100 ml by using mobile phase. Then it was 
filtered  through  membrane  filter;  10  ml  of  this 
solution further diluted to 50 ml with same solvent to 
get 80μg/ml of MET and 200μg/ml of VILD. 
2.6 System suitability
The column efficiency,  resolution and peak 
symmetry were calculated for the standard solutions. 
The values  obtained  demonstrated  the  suitability  of 
the system for the analysis of this drug combination 
and the system suitability parameters fall within ±3% 
standard  deviation range  during performance of  the 
method.  Here  tailing  factor  for  peaks  of  MET and 
VILD  was  less  than  2%  and  resolution  was 
satisfactory.  The peaks  obtained  for  MET HCl and 
VILD were sharp and have clear base line separation. 
The results  of  system suitability tests  are  shown in 
Table 1.
3. Results and Discussion
The  chromatographic  conditions  were 
optimized  to  develop  RP-HPLC  method  for 
simultaneous determination of MET and VILD with 
adequate resolution and rapid analysis time.
3.1 Method Validation
The developed chromatographic method for 
simultaneous  estimation  of  MET  and  VILD  was 
validated  according  ICH  guidelines  for  linearity, 
accuracy,  precision,  specificity,  robustness  and 
ruggedness. 
3.1.1 Linearity
The  response  for  the  detector  was 
determined to be linear over the range of 50-150μg/ml 
(50, 75, 100, 125, 150) of MET and VILD. Each of 
this  concentration  was  injected  to  get  reproducible 
response.  The  calibration  curve  was  plotted  as 
concentration  of  the  respective  drug  versus  the 
response  at  each  level.  The  proposed  method  was 
evaluated by its correlation coefficient  and intercept 
value calculated in the statistical study. The results of 
the linearity studies are shown in Table 2.
3.1.2 Recovery
The accuracy of the method was determined 
by recovery experiments. The recovery studies were 
carried out using standard addition method at 50, 100 
and  150 % level;  known amount  of  standards  was 
added to reanalyzed sample and subjected them to the 
proposed  HPLC  method.  Percentage  recovery  was 
calculated from the amount found and actual amount 
added. The mean recovery is within acceptable limits 
which indicate that the method is accurate .The results 
of recovery studies are shown in Table 3.
3.1.3 Precision
The  precision  of  an  analytical  method  is 
expressed  in  terms  of  SD  or  RSD  of  series  of 
measurements.  It  was  ascertained  by  replicate 
estimation of MET and VILD by proposed method. 
Percentage  relative standard  deviation (%RSD) was 
found to be less than 2% which proves that method is 
precise.  The results of precision study are shown in 
Table 4.
3.1.4 Specificity of the method
The specificity of the method was checked 
for the interference of impurities in the analysis of a 
blank solution (without any sample) and then a drug 
solution of  20 μg/ml was injected into the column, 
under  optimized  chromatographic  conditions  to 
demonstrate the separation of both MET and VILD 
from any of the impurities, if present. As there was no 
interference of impurities and also no change in the 
retention time, the method was found to be specific 
and  also  confirmed  with  the  results  of  analysis  of 
tablet formulation. The mean retention time for MET 
and  VILD  was  found  to  be  1.503  and  5.530  min 
respectively.
3.1.5 Ruggedness
The  ruggedness  studies  were  performed 
under  different  conditions,  Inter-day  and  Intra-day. 
Inter-day studies  were  performed on different  days, 
day1;  day2  and  day3  whereas  intra-day  study  was 
performed at 3 hrs interval within a day. The results 
of ruggedness study are shown in Table 5.
3.1.6 Robustness
Robustness  of  the  method  was  determined 
by  making  slight  changes  in  the  experimental 
conditions such as the, pH of the mobile phase, and 
flow  rate  of  the  mobile  phase  and  the 
chromatographic  characteristics  were  evaluated.  It 
was observed that there were no marked changes in 
the chromatograms, which demonstrated that, the RP-
HPLC method developed, are rugged and robust. The 
results of robustness study are shown in Table 6. 
3.2 Application of the method in tablets 
Equal  volume (20μL)  of  working  standard 
solution of MET and VILD and sample solution were 
injected  and  chromatograms  were  recorded  and 
evaluated.  The procedure  was  repeated  three  times, 
individually  weighing  the  tablet  powder  each  time. 
The  responses  from  the  standard  and  sample  were 
used to calculate the amounts of the drug in the tablet. 
Results  obtained  are  shown  in  Table  7.  The 
chromatogram showing separation of MET and VILD 
in tablet formulation is shown in figure 3.
4. Conclusion
The  developed  RP-HPLC  method  for 
simultaneous  estimation  of  MET  and  VILD  in 
combined tablet dosage forms is simple, sensitive and 
reproducible. Therefore it can be used in routine for 
simultaneous estimation of MET and VILD in bulk as 
well  as  in pharmaceutical  preparations.  The various 
validation characteristics for developed method were 
studied to find out the suitability of the method. It was 
found  to  be  valid  and  suitable  for  its  intended 
purpose.
38
Research Article                                                                                                 Shelke et al /2013
Acknowledgment
The  Authors  extends  their  thanks  to  P. 
Wadhwani  College  of  Pharmacy,  Yavatmal  for 
providing  necessary  facilities  for  successful 
completion of this work.
References
1. Jain AK, Agrawal RK. Simultaneous Estimation 
Of Gliclazide And Metformin Hydrochloride In 
Combined  Dosage  Forms.  Indian  Journal  of 
Pharmaceutical Sciences 2002; 64(1):88-91.
2. AbuRuz  S,  Millership  J,  McElnay  J.  The 
development  and  validation  of  liquid 
chromatography method  for  the  simultaneous 
determination  of  metformin  and  glipizide, 
gliclazide,  glibenclamide  or  glimperide  in 
plasma.  Journal  of  Chromatography  B  2005; 
817(2):277-286.
3. Hossein  A,  Abolhassan  A,  Parisa  G. 
Determination of metformin in human plasma by 
high-performance  liquid  chromatography. 
Journal  of  Chromatography  B  2005;824(1-2): 
319-322. 
4. Cristina  G,  Florin  A,  Victor  D,  Andrei  M. 
Simultaneous  assay  of  metformin  and 
glibenclamide  in  human  plasma  based  on 
extraction-less sample preparation procedure and 
LC/(APCI)MS.  Journal  of  Chromatography  B 
2007;854(1-2):211-218.
5. Osadebe PO, Akabogu IC. Assessment of quality 
control  parameters  and  interchangeability  of 
multisourced metformin HCl tablets marketed in 
Nigeria.  Bollettino  Chimico  Farmaceutico, 
2004;143(4):170-173.
6. Marques MA, Soares AS, Pinto OW, Barroso PT, 
Pinto DP, Ferreira FM, Barroso EW. Simple and 
rapid  method  determination  for  metformin  in 
human  plasma  using  high  performance  liquid 
chromatography  tandem  mass  spectrometry: 
Application to  pharmacokinetic  studies.  Journal 
of Chromatography B 2007; 852(1-2):308-316.
7. Mistria HN, Jangid AG. Liquid chromatography 
tandem  massspectrometry  method  for 
simultaneous determination of antidiabetic drugs 
metformin  and  glyburide  in  human  plasma. 
Journal  of  Pharmaceutical  and  Biomedical 
Analysis 2007; 45(1):97-106.
8. Wang Y, TangY, Gu J, Fawcett JP, Bai X. Rapid 
and  sensitive  liquid  chromatography–tandem 
mass spectrometric method for the quantitation of 
metformin  in  human  plasma.  Journal  of 
Chromatography B 2004;808(2):215-219.
9. Chen  X,  Gu  Q,  Qiu  F,  Zhong  D.  Rapid 
determination of metformin in human plasma by 
liquid  chromatography-tandem  mass 
spectrometry  method.  Journal  of 
Chromatography B 2004; 802 (2):377-381.
10. Lalhriatpuii  TC,  Kawathekar  N.  Derivative 
spectrophotometric  estimation  of  Pioglitazone 
and  Metformin  hydrochloride.  Indian  Drugs 
2005; 42(11):740-743.
11. Ajithdas A, Nancy K. Simultaneous estimation of 
Metformin hydrochloride and Glipizidin in solid 
dosage  forms  by  ultraviolet  spectrophotometry. 
Indian Drugs 2000; 37(11): 533-536.
12. Bhanu R,  Kulkarni  S,  Kadam A.  Simultaneous 
estimation  of  Gliclazide  and  Metformin  in 
pharmaceutical  dosage by reverse phase HPLC. 
Indian Drugs 2006; 43(1):16-20.
13. Bretnall  AE,  Clarke  GS.  Chromatographic 
method of analysis of Metformin hydrochloride. 
In:  Brittain,  H.G.,  editor;  Analytical  Profiles of 
drug  substances  and  excipients.  New  York: 
Academic Press 1998; 25:243-58.
14. Charles  BG,  Jascoben  NW,  Ravenscroft  PJ. 
Rapid  liquid  chromatographic  determination  of 
Metformin  in  plasma  and  urine.  Clinical 
Chemistry 1981;27(3):434-436.
15. Lad  NR,  Bhoir  SI,  Bhoir  IC,  Sundaresan  M. 
Concurrent assay of Metformin and Glimepiride 
in  tablet  using  RP-HPLC  with  wavelength 
programming.  Indian  Journal  of  Pharmaceutical 
Sciences 2003; 65(6):650-653.
16. Yuen KH, Peh KK. Simple HPLC method for the 
determination  of  Metformin  in  human  plasma; 
Journal  of  Chromatography  B  1998;  710(1-
2):243-246.
17. Pareek A, Chandurkar N, Zawar S, Agrawal N. 
Evaluation  of  efficacy  and  tolerability  of 
gliclazide  and  metformin  combination:  a 
multicentric study in patients with type 2 diabetes 
mellitus  uncontrolled  on  monotherapy  with 
sulfonylurea or Metformin. American Journal of 
Therapeutics 2010; 17(6):559-565.
18. Filozof C, Gautier JF. A comparison of efficacy 
and  safety  of  vildagliptin  and  gliclazide  in 
combination  with  metformin  in  patients  with 
Type  2  diabetes  inadequately  controlled  with 
metformin alone:  a  52-week  randomized study. 
Diabetic Medicine 2010;27(3):318–326.
Table 1. System suitability test results
Sr. No. Parameters MET VILD
1. Peak area 6722 6109
2. No. of theoretical plates 3079.01 12034.26
3. Retention time (min) 1.503 5.530
4. Asymmetry 1.89 1.95
39
Research Article                                                                                                 Shelke et al /2013
Table 2. Linearity study data
Sr. No. Drugs Slope Intercept Correlation Coefficient (R2)
1 MET 67.025 37.786 0.999
2 VILD 61.847 12.656 0.998
Table 3. Recovery study data
Sr. No. Drug % Recovery %RSD
1 Metformin HCl 100.17 1.20
2 Vildagliptin 99.98 0.19
Table 4. Precision study data
Sr. No. Wt. of Sample
(mg)
Peak area of Std. Peak area of Std. % Label Claim
MET VILD MET VILD MET VILD
1.
2.
3.
635.25 6722 6109
6702 6137 99.70 100.45
6739 6105 100.25 99.93
6725 6123 100.04 100.22
Mean 99.99 100.2
S.D. 0.27 0.26
%RSD 0.27 0.26
Table 5. Ruggedness study data
MET (% Recoveries) VILD (% Recoveries)
Intra-day 
studies
T1 100.07 100.01
T2 100.1 99.81
T3 99.86 99.44
Mean 10.03 99.75
% RSD 0.13 0.29
MET (% Recoveries) VILD (% Recoveries)
Inter-day 
studies
D1 99.70 100.45
D2 100.25 99.93
D3 100.04 100.22
Mean 99.99 100.2
%RSD 0.27 0.26
    T1,T2 and T3 are Time1,Time2 and Time3 in intra-day studies.
    D1,D2 and D3 are Day1,Day2 and Day3 in inter-day studies 
Table 6. Robustness study data
System suitability Parameters % RSD of peak 
area response
(n=3)
Mean tailing factor
(n=3)
Mean retention 
time in min.
(n=3)
Variations MET VILD MET VILD MET VILD
Change in flow Rate +10 1.74 1.63 1.66 1.43 1.58 1.64
0 1.21 1.20 1.65 1.59 1.73 1.31
-10 1.21 1.25 1.32 1.73 1.29 1.74
Change in % Organic 
phase (Methanol)
+10 1.21 1.65 1.35 1.27 1.23 1.60
0 1.21 1.20 1.65 1.59 1.77 1.31
-10 1.04 1.29 1.73 1.22 1.50 1.71
Change in pH +0.2 1.56 1.78 1.76 1.26 1.80 1.30
0 1.21 1.20 1.65 1.59 1.77 1.31
-0.2 1.75 1.36 1.88 1.51 1.45 1.58
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Table 7. Results of Tablet formulation study
Sr. No. Weight of std.  (mg) Weight of sample Peak area of std Peak area of sample % Label claimMET HCl VILD (mg) MET HCl VILD MET HCl VILD MET HCl VILD
1.
500 50
635.27
6722 6109
6751 6112 100.43 100.04
2. 635.19 6749 6098 100.40 99.81
3. 635.09 6734 6105 100.17 99.93
Mean 100.33 99.92
S.D. 0.14 0.11
% RSD 0.14 0.11
Figure 1. Structure of a) Metformin HCL and b) Vildagliptin
Figure 2. Typical HPLC chromatogram corresponding to mixed standard solution of  VILD and MET
Figure 3.  Typical HPLC Chromatogram corresponding to  marketed formulation of VILD and MET
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